SCHEMBL435819

SCHEMBL435819

O=C(O)Cn1c(=O)c1=O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11800863 0.82 ALDH1A1 (0.52)
SCHEMBL1729618 0.82 APEX1 (0.42)
SCHEMBL677187 0.81 APEX1 (0.62)
SCHEMBL6910658 0.80
SCHEMBL18180193 0.78 APEX1 (0.77)
SCHEMBL24439070 0.75 ALDH1A1 (0.46)
SCHEMBL7337432 0.75 APEX1 (0.45)
SCHEMBL24439301 0.72 GRIA1 (0.46)
SCHEMBL4184455 0.71 APEX1 (0.47)
SCHEMBL20967578 0.71 APEX1 (0.52)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 429 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260124274-A1 METHODS OF INCREASING READTHROUGH OF A PREMATURE TERMINATION CODON UNIV RAMOT (IL) 2026-05-07 US claimed
US-20260027096-A1 PHD INHIBITORS UNIV OXFORD INNOVATION LTD (GB) 2026-01-29 US claimed
EP-4655288-A1 PHD INHIBITORS Oxford University Innovation Limited (GB) 2025-12-03 EP claimed
US-20250319119-A1 COMPOSITIONS AND METHODS THAT PROMOTE HYPOXIA OR THE HYPOXIA RESPONSE FOR TREATMENT AND PREVENTION OF MITOCHONDRIAL DYSFUNCTION AND OXIDATIVE STRESS DISORDERS MASSACHUSETTS GEN HOSPITAL (US) 2025-10-16 US claimed
EP-3936608-B1 REPROGRAMMING CELLS SCRIPPS RESEARCH INST (US) 2025-05-07 EP claimed
US-20250066735-A1 PREPARATION METHOD OF MESENCHYMAL STEM CELL (MSC) AND APPLICATION THEREOF IN KNEE PRODUCT GUANGDONG CELL BIOTECHNOLOGY CO. LTD (CN) 2025-02-27 US claimed
EP-4512819-A2 COMPOSITIONS AND METHODS THAT PROMOTE HYPOXIA OR THE HYPOXIA RESPONSE FOR TREATMENT AND PREVENTION OF MITOCHONDRIAL DYSFUNCTION AND OXIDATIVE STRESS DISORDERS The General Hospital Corporation (US) 2025-02-26 EP claimed
CN-118497122-B Preparation method of mesenchymal stem cells and application of mesenchymal stem cells in knee joint products 广东赛尔生物科技有限公司 2024-10-15 CN claimed
CN-118497122-A Preparation method of mesenchymal stem cells and application of mesenchymal stem cells in knee joint products 广东赛尔生物科技有限公司 2024-08-16 CN claimed
WO-2024157019-A1 PHD INHIBITORS OXFORD UNIVERSITY INNOVATION LIMITED (GB) 2024-08-02 WO claimed
WO-2008155556-A1 A METHOD FOR ASSAYING FTO (2-OXOGLUTARATE DEPENDENT OXYGENASE) ACTIVITY ISIS INNOVATION LIMITED (GB) 2008-12-24 WO claimed
EP-1929035-A1 MINA53 ASSAYS ISIS INNOVATION LIMITED (GB) 2008-06-11 EP claimed
EP-1912637-A2 INHIBITORS OF EGLN3 ACTIVITY FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS DANA-FARBER CANCER INSTITUTE, INC. (US) 2008-04-23 EP claimed
WO-2007034214-A1 MINA53 ASSAYS ISIS INNOVATION LIMITED (GB) 2007-03-29 WO claimed
WO-2007009044-A2 INHIBITORS OF EGLN3 ACTIVITY FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS DANA FARBER CANCER INSTITUTE, INC. (US) 2007-01-18 WO claimed
EP-1451341-A4 EIT-6, A POLYPEPTIDE ENCODED BY AN ESTROGEN REGULATED GENE DANA FARBER CANCER INST INC (US) 2005-07-13 EP claimed
US-20040248139-A1 Eit-6, a polypeptide encoded by an estrogen regulated gene DANA-FARBER CANCER INSTITUTE, INC. 2004-12-09 US claimed
EP-1451341-A2 EIT-6, A POLYPEPTIDE ENCODED BY AN ESTROGEN REGULATED GENE DANA-FARBER CANCER INSTITUTE, INC. (US) 2004-09-01 EP claimed
WO-2004058252-A2 ANTI-CANCER AGENTS COMPRISING ALKB INHIBITORS AND ALKYLATING AGENTS ISIS INNOVATION LIMITED (GB) 2004-07-15 WO claimed
WO-2003042363-A2 EIT-6, A POLYPEPTIDE ENCODED BY AN ESTROGEN REGULATED GENE DANA-FARBER CANCER INSTITUTE, INC. (US) 2003-05-22 WO claimed